Noticias de ATAI | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AT

Cap. mercado

N/A

Volumen

N/A

Próximos resultados

N/A

Gráfico Tesorería en bitcoin Resultados Noticias Acerca de Dividendos Insiders Reportes

Why Eli Lilly Stock Climbed TodayEli Lilly's stock rose 4.86% following strong second-quarter earnings driven by surging sales of its obesity drugs Mounjaro and Zepbound, which grew 91% and 44% respectively. The company reported Q2 revenue of $23 billion (up 48% YoY) and adjusted net income of $7.5 billion, exceeding Wall Street expectations. Management raised its full-year revenue guidance to $85-87 billion and is investing profits into pipeline development through strategic acquisitions.The Motley Fool · Aug 5, 2026

Why AtaiBeckley Stock Soared TodayAtaiBeckley shares surged 33.40% after pharmaceutical giant Eli Lilly agreed to acquire the mental health-focused biotechnology company for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The total deal valuation could reach approximately $3.8 billion if all conditions are met. The acquisition is expected to close in Q3, subject to shareholder and regulatory approval.The Motley Fool · Jul 16, 2026

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive DisorderAtaiBeckley completed enrollment in its Phase 2b Elumina trial for VLS-01, a DMT-based oral film treatment for treatment-resistant depression, with 156 patients randomized. The company plans to advance VLS-01 into Phase 3 development for major depressive disorder and generalized anxiety disorder, pending positive Phase 2 results expected in Q4 2026. VLS-01 will complement BPL-003, which is already in Phase 3 for TRD with Breakthrough Therapy Designation.GlobeNewswire Inc. · Jul 6, 2026

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biotechnology company developing mental health treatments, announced participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, HCW Neuro Perspectives Conference, and UBS Virtual CNS Day. The company is advancing its pipeline including BPL-003 for treatment-resistant depression in Phase 3 planning, VLS-01 and EMP-01 in Phase 2 development.GlobeNewswire Inc. · May 27, 2026

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderAtaiBeckley reported expanded Phase 2a trial results for EMP-01 (oral R-MDMA) in social anxiety disorder, demonstrating 49% responder rates and clinically meaningful improvements across multiple symptom measures (LSAS, SPIN, SAFE) with a favorable safety profile and no serious adverse events. The treatment showed a 38% reduction in patient-reported symptoms versus 15% on placebo, with durability observed after just two administrations over 28 days.GlobeNewswire Inc. · Apr 22, 2026

AtaiBeckley to Participate in Upcoming Needham Healthcare ConferencesAtaiBeckley Inc. announced that Co-Founder and CEO Dr. Srinivas Rao will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13-16) and the Needham Virtual Psychedelics Forum (April 27). The company's lead candidate BPL-003 (mebufotenin benzoate nasal spray) has received FDA Breakthrough Therapy Designation and is on track to enter Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.GlobeNewswire Inc. · Apr 14, 2026

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 InitiationAtaiBeckley Inc. announced peer-reviewed Phase 2a results for BPL-003 (mebufotenin benzoate nasal spray) in treatment-resistant depression, showing a mean MADRS score reduction of 12.6 points by Day 2 that was sustained over 12 weeks. The drug demonstrated a 54.5% response rate and 63.6% remission rate with good tolerability. The Phase 3 program remains on track for initiation in Q2 2026 following a successful FDA End-of-Phase 2 meeting.GlobeNewswire Inc. · Mar 17, 2026

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical UpdateAtaiBeckley announced Q4 2025 financial results with $220.7M in cash runway through early 2029. The company received FDA approval to advance BPL-003 (mebufotenin benzoate nasal spray) into Phase 3 trials for treatment-resistant depression, with initiation planned for Q2 2026. EMP-01 (oral R-MDMA) met primary safety objectives in a Phase 2a social anxiety disorder trial with clinically meaningful efficacy improvements. VLS-01 Phase 2 data is anticipated in H2 2026.GlobeNewswire Inc. · Mar 6, 2026

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsFive psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.Benzinga · Feb 27, 2026

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic PresentationAtaiBeckley presented clinical and preclinical data at the 64th Annual ACNP Meeting in Nassau, Bahamas. The company's Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray for treatment-resistant depression showed significant rapid and sustained antidepressant effects at 8mg and 12mg doses compared to control, with good tolerability. The presentation was selected for the prestigious Hot Topics Session. Additionally, preclinical data on 5-MeO-DMT's pharmacology and potential neuroplasticity effects were presented.GlobeNewswire Inc. · Jan 16, 2026

AT

ATAIATAI

ATAI

Pagar con—

Empezar a operar

Saldo disponible0,00

Tu posiciónAún no tienes ATAI.

Tickers relacionados

Resultados

Dividendos

Último · Sep 9

Importe$6.75

Rendimiento91.84%

Anual$6.75